Asciminib for relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia ashpublications.org/bloodadvances/… #leusm

This partnership underscores our dedication to patient-centered care by ensuring those traveling to Moffitt Cancer Center will have access to high-quality accommodations in close proximity to our Moffitt McKinley Hospital, Outpatient Center and Magnolia campus.

👇👇 in case you missed it 👇👇

New findings in @SciSignal reveal how a co-receptor named TIM3 on T cells functions differently depending on its cellular context—a discovery that could aid in the development of drugs that target this co-receptor. scim.ag/482IW6a

At #ASTRO25, Nicholas Figura, MD, (Nick Figura, MD) discusses challenging radiotherapy cases during an education session, sharing insights on a patient who received bridging RT before CAR T-cell therapy. #MoffittASTRO25

This weeks IMO research in progress is from Jeffrey West lab member Sadegh Marzban presenting: "Mechanistic Model in B-ALL" Moffitt Cancer Center

x.com/i/article/1978…

Lymphoma accelerates T cell and tissue aging dlvr.it/TNhzV1

We are excited to kick off the second annual Cell Coast Conference, presented by Moffitt Cancer Center! Stay tuned as oncologists share the latest updates in cellular therapy. Follow along at #CellCoast25 for updates!

That’s a wrap on the 2025 Cell Coast Conference! Thank you to all who contributed to this dynamic meeting focused on advancing cellular therapies. Your insights, collaboration and innovation are bridging the gap between cancer research and care. #CellCoast25 #CellTherapy

Great time at #CellCoast25 with Frederick L. Locke and the Moffitt Cancer Center team!

Sanam Loghavi, MD صنم لغوی 🔬🧬 Anand Patel Kamran Mirza MD PhD - کامران مرزا Hannah Goulart Heme Reports Hematology Cancer Consortium Vikram Mathews Manju Sengar Hasmukh Jain bshah Congratulations Julie Julie Braish 👍👍🙏🏽🙏🏽👏👏

Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Follicular Lymphoma: apparent plateaus forming on K-M PFS curves. Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

How well do bsAbs work for patients with DLBCL who relapse after CAR T? depends on time to relapse post-CAR... ORR similar, however CR and OS were significantly lower in those with refractory/early relapsed disease. led by Megan Melody MD, MS and #ReemKarmali doi.org/10.1182/blooda…

Late failure of aggressive B-cell lymphoma following CAR T-cell therapy: a LYSA study from the DESCAR-T registry ⁦Blood Advances⁩ ‘failure’ after 3 months from CAR T infusion Bispecific antibodies improve PFS after CAR T relapse cf other therapies ashpublications.org/bloodadvances/…

As I start working on a new IST concept, just thought of reposting this thread from 2022

Live from #SITC25: Daniel Abate-Daga, PhD, shares that CAR-TIL demonstrates potent tumor recognition and superior infiltration compared with traditional CAR-T cells. Key takeaways: • Murine TIL concentrate in tumors after adoptive transfer and gradually acquire EM phenotype.

Live from #SITC25: Andreas Saltos, MD joins us to discuss exciting data from the HARMONi study and what it means for NSCLC treatment. #MoffittSITC25

This represents the largest data set for any chimeric antigen receptor T-cell therapy in pediatric and young adult patients with B-ALL. ow.ly/tw9f50XjKhW #genetherapy #lymphoidneoplasia

Proud of our fellows for maintaining the tradition of a strong presence of Moffitt Hematology/Oncology Fellowship at ASH 💪😇 Can’t wait to celebrate their success close to home in Orlando this year at #ASH25 🌴